Amneal Pharmaceuticals Inc. has released its 2024 Responsible Business Report, detailing progress in environmental, social, and governance $(ESG)$ initiatives. The report outlines efforts to enhance healthcare access, promote environmental sustainability, and support workforce development. Key highlights include the introduction of a new ESG framework structured around societal impact, environmental impact, and people & practices. In 2024, Amneal filled over 162 million prescriptions in the U.S., launched 22 new generic products, and addressed drug shortages by producing over 10 critical injectable medicines. Environmental efforts included transitioning a manufacturing facility in India from coal to biomass, reducing CO₂ emissions by 1,600 tons annually, and supporting tree planting initiatives. The company also launched a global talent development framework and reported an increase in employee engagement. The full report aligns with global standards and is available on Amneal's website.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。